腹腔镜Nissen和Toupet胃底折叠术治疗食管裂孔疝合并胃食管反流病的术后效果评价

目的探讨腹腔镜Nissen和Toupet胃底折叠术治疗食管裂孔疝合并胃食管反流病的疗效和术后并发症。 方法回顾性分析2014年7月至2016年7月,在中国医科大学附属盛京医院行腹腔镜下食管裂孔疝修补联合胃底折叠术的57例食管裂孔疝合并胃食管反流病患者的临床资料,其中24例行Nissen胃底折叠术式(Nissen组),33例行Toupet胃底折叠术式(Toupet组)。观察并比较2组患者的术后抗反流效果及发生术后并发症情况。 结果57例均顺利完成腹腔镜下手术,无中转开腹,手术时间68～115 min,平均手术时间(75.8±6.4)min;术中出血量15～30 ml,平均出血量(22±5)ml;2组患者均使用补片行食管裂孔疝修补术;术后24 h进流食,术后平均住院日(10.5±3)d。2组患者手术时间,出血量,住院日无明显差别。57例患者均得到随访,随访时间为6个月至2.5年,平均随访时间为18个月。术后均未出现反酸,烧心等胃食管反流病典型症状,无复发病例。Nissen组术后有2例(8.2%)患者出现吞咽困难,Toupet组术后有8例(24.2%)出现吞咽困难,Toupet组术后并发症发生率明显高于Nissen组。术前伴有胃食管反流病的患者行胃镜检查均有不同程度的食管炎症,所有患者术后均复查胃镜、食管测压及食管24 h pH值监测。复查结果显示,2组患者术后较术前食管下括约肌压力均有明显改善,食管下括约肌长度也均明显延长。 结论腹腔镜下Nissen术式在术后出现吞咽困难发生率上少于Toupet术式,但2种术式抗反流效果无明显差异。     

聚丙烯补片在腹腔镜下食管裂孔疝修补联合胃底折叠术的临床应用

目的探讨聚丙烯补片在腹腔镜下食管裂孔疝修补联合胃底折叠术治疗食管裂孔疝合并胃食管反流病的临床疗效。 方法回顾性分析新疆维吾尔自治区人民医院2013年5月至2015年3月,住院治疗并使用聚丙烯补片(强生PHY补片)行腹腔镜下食管裂孔疝修补术联合胃底折叠术的38例患者临床资料,总结上述患者术前、术后6个月24 h食管pH监测、高分辨率食管测压、胃食管反流病调查问卷(GERD-Q)量表评分及术后并发症特点。 结果全部患者手术顺利无中转术式等情况,其中Nissen术式27例,Toupet术式8例,Dor术式3例。术后患者反流症状均较术前明显改善,术后反流时间、反流次数、DeMeester评分、GERD-Q量表评分等较术前明显降低,差异有统计学意义(P<0.05),术后出现吞咽困难3例,腹部胀气2例,随访过程中无严重并发症发生,无复发。 结论使用聚丙烯补片行腔镜食管裂孔疝修补联合胃底折叠术是治疗食管裂孔疝的有效方法,具有微创、恢复快、并发症少、复发率低等特点。     

食管裂孔疝合并胃食管反流病合并胃间质细胞瘤的外科治疗

目的探讨食管裂孔疝合并胃食管反流病合并胃间质细胞瘤患者的围手术期处理及安全性。 方法统计新疆维吾尔自治区人民医院2012年10月至2015年1月收治的17例食管裂孔疝合并胃食管反流病合并胃间质细胞瘤患者的病案资料,均采用腹腔镜下微创手术,其中单纯食管裂孔疝缝合者13例,生物补片修补者3例,强生PHY补片修补者1例。抗反流术式中行Nissen式胃底折叠术者8例,Dor式胃底折叠术者6例,Toupet式胃底折叠术者3例。病理结果提示极低危险度胃间质细胞瘤8例,低度危险度者4例,中度危险度者3例,高度危险度者1例,极高危险度者1例,回顾性总结分析该类患者围手术期的处理措施。 结果本组患者无围手术期死亡,术后无严重并发症发生,术后患者反流症状均较术前明显改善,反流时间、反流次数、酸反流时间百分比、长反流次数及DeMeester评分较术前明显降低(P<0.05),术后GERD Q量表评分较术前明显减低(P<0.05);LES压力较术前明显提高(P<0.05)。术后切口感染1例,慢性疼痛1例,给予换药、理疗后好转。2例患者术后出现进食哽噎,1例患者术后出现腹泻,嘱其少量多餐、细嚼慢咽,1个月后症状消失。合并贫血患者术后血红蛋白恢复至95 g/L,术后随访中位数10个月,无复发病例。 结论食管裂孔疝合并胃食管反流病合并胃间质细胞瘤患者病情较复杂使得手术风险大,难度高,但只要作好充分的术前准备,采用恰当的手术方式,术中谨慎、细致操作,针对性的处理术后出现的各种问题,仍是安全可行的。     

腹腔镜胃底折叠术联合胆囊切除术治疗反流性食管炎合并胆囊结石、胆囊息肉27例

目的观察腹腔镜胃底折叠术联合胆囊切除术治疗反流性食管炎合并胆囊结石、胆囊息肉的临床效果。方法反流性食管炎合并胆囊结石、胆囊息肉的患者27例,均行腹腔镜胃底折叠术联合胆囊切除术治疗。观察反酸、胸骨后疼痛及上腹疼痛减轻情况。分别于术后6个月、1年行24 h动态胃酸监测、食管下端测压。结果 27例均顺利完成手术,无中转开腹及死亡病例。术后出现胆囊床积液、尿潴留、轻度吞咽困难各1例,轻度反酸2例,经相应处理后均治愈出院。随访9～15个月,平均(10.23±3.78)个月,3例可见轻度酸反流,予抑酸药物治疗可控制。术后反流性食管炎及胆囊结石相关症状均好转,术后6个月、1年食管下端压力分别为(18.79±2.13)、(21.62±1.81)mmHg,均高于术前的(7.14±1.29)mmHg(P均<0.01)。术后6个月、1年24 h胃酸pH监测DeMeester评分分别为(7.64±2.13)、(7.71±2.34)分,均低于术前的(177.63±11.35)分(P均<0.01)。结论腹腔镜胃底折叠术联合胆囊切除术治疗反流性食管炎合并胆囊结石、胆囊息肉安全、有效。     

腹腔镜食管裂孔疝修补术联合胃底折叠术联合胆囊切除术的疗效分析

目的探讨腹腔镜食管裂孔疝修补术联合胃底折叠术联合胆囊切除术治疗食管裂孔疝合并胃食管反流病合并胆囊结石患者的临床疗效。 方法回顾性分析新疆维吾尔自治区人民医院2012年8月至2016年8月,收治的27例行腹腔镜食管裂孔疝修补术联合胃底折叠术联合胆囊切除术治疗食管裂孔疝合并胃食管反流病合并胆囊结石患者的临床资料,其中单纯食管裂孔疝修补患者22例,生物补片修补患者2例,强生PHY补片修补患者1例,巴德补片修补患者1例,泰科食管裂孔疝专用防粘连补片修补患者1例。统计上述患者术前及术后6个月的24 h食管pH、食管测压、GERD-Q量表评分及术后并发症等,回顾性分析腹腔镜食管裂孔疝修补术联合胃底折叠术联合胆囊切除术治疗食管裂孔疝合并胃食管反流病合并胆囊结石的临床疗效。 结果本组患者无围手术期死亡,术后无严重并发症发生,术后患者反流症状均较术前明显改善,反流时间(1.40±2.10)h、反流次数(29.83±19.71)次、酸反流时间百分比(6.47±8.79)%、及DeMeester评分(7.28±7.38)分、GERD-Q量表评分(7.18±1.33)分较术前分别为(2.04±1.91)h、(120.40±82.72)次、(9.90±9.27)%、(28.23±42.16)分、(10.91±2.02)分明显降低,差异有统计学意义(P<0.05);术后LES压力中的静息呼吸最小值为(7.24±6.86)mmHg,静息呼吸平均值为(12.91±6.89)mmHg,较术前分别为(0.70±6.15)mmHg、(7.33±7.72)mmHg明显提高,残余压平均值为(8.16±3.82)mmHg,最大值为(16.10±12.05)mmHg,较术前分别为(4.36±4.77)mmHg、(7.49±5.15)mmHg明显提高,差异有统计学意义(P<0.05);术后松弛率(58.50±25.47)%]较术前[(62.27±27.55)%明显降低,但术后无效吞咽百分比(11.25±21.04)%较术前(6.36±10.26)%略有增加,差异无统计学意义(P>0.05)。随访中位数10个月,随访过程中无复发。 结论腹腔镜食管裂孔疝修补术联合胃底折叠术联合胆囊切除术可有效抑制反流症状,提高LES压力,解决患者病痛,疗效确切,值得临床推广。     

腹腔镜胃底折叠术治疗胃食管反流性疾病

目的　探讨腹腔镜胃底折叠术治疗胃食管反流性疾病的可行性及安全性。方法　回顾性分析 2 0 0 1年 6月至 2 0 0 4年 3月对 4 2例行腹腔镜胃底折叠术的胃食管反流性疾病患者的临床资料。结果　 33例行腹腔镜Nissen胃底折叠术 ,9例行腹腔镜Toupet胃底折叠术。术后症状评分由11 5 6± 1 32降到 2 0 4± 1 36 ,食管下段压力由 (7 32± 1 34)mmHg提高到 (18 2 0± 3 4 3)mmHg ,2 4hpH值监测评分由 183 36± 96 76降低到 8 0 4± 2 12 ,均较手术前有明显改善 (P <0 0 1) ,并达到正常范围。无手术并发症 ,无中转开腹及死亡病例。结论　对于严重的胃食管反流性疾病 ,腹腔镜胃底折叠术是一种安全、有效的治疗方法     

腹腔镜180°前胃底折叠术治疗胃食管反流性疾病的长期随访结果

目的评价腹腔镜180。前胃底折叠术治疗胃食管反流性疾病的远期效果。方法2004年7月至2007年9月,48例胃食管反流性疾病患者接受腹腔镜180。前胃底折叠术,术后3个月、12个月、3年、5年及之后每年通过电话或邮寄信件以标准化问卷的形式,对其进行随访,评估烧心、吞咽困难等症状以及术后并发症、整体满意度情况。结果获得43例随访数据,随访时间60～98个月,平均78个月。最近的一次随访结果显示：37例烧心症状消失或偶尔出现,40例患者可正常嗳气,38例患者可以正常进食,39例（90．7％）患者对术后效果满意。2例患者分别于术后12个月和38个月因反酸再次行腹腔镜胃底折叠术手术,效果良好。结论腹腔镜180。前胃底折叠术治疗胃食管反流性疾病是一种持久有效的术式,大多数患者对术后长期效果满意。     

腹腔镜食管裂孔疝修补联合胃底折叠术治疗食管裂孔疝合并胃食管反流的临床疗效观察

目的观察腹腔镜食管裂孔疝修补联合胃底折叠术治疗食管裂孔疝合并胃食管反流的临床疗效。方法选择2015-02~2016-04该院收治的80例食管裂孔疝合并胃食管反流患者,按随机数字表法分为两组,各40例。对照组实施常规开腹手术治疗,观察组实施腹腔镜食管裂孔疝修补联合胃底折叠术治疗。比较两组患者各项手术指标、生存质量、并发症发生情况以及术后病情状况。结果观察组术中出血量、胃肠道功能恢复时间、手术时间、住院时间均短于对照组,差异有统计学意义(P0.01);观察组胸痛、烧心感、反食、反酸评分均低于对照组,差异有统计学意义(P0.01);观察组GLQI评分与对照组相比有明显提高,差异有统计学意义(P0.01);观察组并发症发生率明显低于对照组,差异有统计学意义(P0.05)。结论对食管裂孔疝合并胃食管反流患者实施腹腔镜食管裂孔疝修补联合胃底折叠术治疗能有效优化各项手术指标,改善患者病情,提高患者生存质量,降低术后并发症发生率,安全性高,值得临床推广。     

胃食管吻合术联合Nissen胃底折叠术对食管中段癌患者术后胃食管反流的影响

目的探讨胃食管吻合术联合Nissen胃底折叠术对食管中段癌术后患者胃食管反流的影响。 方法选取2015年9月至2017年3月,新疆维吾尔自治区人民医院住院并行食管癌切除术31例食管中段癌患者的临床资料。根据手术方式分为2组,即接受胃食管吻合术联合Nissen胃底折叠术15例（观察组）,接受胃食管吻合术16例（对照组）,术后2周待患者恢复正常的胃肠道功能后采用pH动态监测仪对其进行24 h pH监测,术后1、3、6、12个月依据胃食管反流病调查问卷（GerdQ）对患者的胃食管反流相关症状进行评分,比较2组患者术后胃食管反流发生情况。 结果2组患者均未出现死亡病例,且术后均未发生有吻合口瘘及胸胃排空障碍等并发症;观察组患者术后2周24 h酸反流次数显著少于对照组、最长酸反流时间和pH值<4的总时间短于对照组,DeMeester评分显著低于对照组,组间比较均有统计学意义（P<0.05）;观察组术后3、6、12个月胃食管反流病调查问卷（GerdQ）评分显著低于对照组,组间比较均有统计学意义（P<0.05）。 结论胃食管吻合术联合Nissen胃底折叠术对食管癌切术后的胃食管反流病情起到更为理想的控制效果,为食管中段癌患者术中吻合术式的选择提供一定参考价值。     

胃食管反流病患者胃底折叠术前后食管动力的研究

食管下端括约肌功能障碍是胃食管反流病的主要病因 ,病人常常被建议行胃底折叠术以减少反流的发生。然而 ,食管动力障碍在本病中的作用却知之甚少。本研究旨在确定食管动力异常是否影响胃食管反流病患者的症状和胃底折叠术的临床疗效以及术后是否发生食管运动功能改变。方法　 1 999年 5月～ 2 0 0 0年 5月期间 ,有长期胃食管反流病病史的 2 0 0例病人经临床评估、上消化道内镜检查、食管测压及 2 4ｈｐＨ监测后进入研究。根据是否存有食管动力异常分为两组 (每组 1 0 0例 ) ,随机行Ｎｉｓｓｅｎ或Ｔｏｕｐｅｔ手术治疗。术后进行为期 4个月…     

胰岛素瘤的解剖分布特点分析

目的胰岛素瘤是最常见的胰腺神经内分泌肿瘤，因其临床表现多样，导致诊断困难。影像学诊断尤其是超声内镜(EUS)在胰岛素瘤的诊断中起着重要作用，拥有较高的敏感性和特异性。本研究拟通过明确胰岛素瘤的解剖分布特点，以期有助于提高影像学的诊断准确率和降低漏诊率，尤其是在教育和培训实践中对于EUS的学习者更具有指导价值。 方法回顾性分析解放军总医院第一医学中心病案资料数据库1993年1月至2019年11月经外科手术、病理确诊为胰岛素瘤的患者的临床资料，检索方法采取搜索术后病理诊断为"胰岛素瘤"的病例，通过查阅病例的方法，提取出胰岛素瘤的大小和解剖分布等数据，进一步分析其特点。 结果共检索到确诊为胰岛素瘤的患者116例，其中，男45例、女71例，年龄13～76岁，平均年龄(44.4±14.85)岁。胰岛素瘤单发110例(94.8%)、多发6例(5.2%)。位置分布：头颈部46例(39.7%)，单发45例、多发1例；体尾部68例(58.6%)，单发65例、多发3例；全胰腺多发2例(1.7%)。病变大小特点：最大径0.4～3.4 cm，平均大小(1.53±0.58)cm。≤1 cm 29例、>1 cm而≤1.5 cm41例、>1.5 cm而≤2.0 cm28例，≤3 cm 15例，>3 cm 3例。年龄与肿瘤的大小相关，≤44岁患者肿瘤平均大小为(1.36±0.51)cm、>44岁患者肿瘤平均大小为(1.70±0.60)cm，P<0.05。头颈部的肿瘤大于体尾部的肿瘤，头颈部肿瘤平均大小(1.66±0.63)cm，体尾部(1.42±0.52)cm，P<0.05。 结论胰岛素瘤在胰腺体尾部较头颈部更好发；绝大多数单发，但可以全胰腺多发；多数小于1.5 cm，肿瘤的大小与患者年龄和肿瘤的解剖分布相关。     

Pathogenesis of carcinoma of the papilla of Vater

Most adenomas and carcinomas of the small intestine and extrahepatic bile ducts arise in the region of the papilla of Vater. In familial adenomatous polyposis (FAP) it is the main location for carcinomas after proctocolectomy. In many cases symptoms due to stenosis lead to diagnosis at an early tumor stage. In about 80%, curative intended resection is possible. Operability is the most relevant prognostic factor. Most ampullary carcinomas resp. carcinomas of the papilla of Vater develop from adenomatous or flat dysplastic precursor lesions. They can be sited in the ampulloduodenal part of the papilla of Vater, which is lined by intestinal mucosa. They also can develop in deeper parts of the ampulla, which are lined by pancreaticobiliary duct mucosa. Intestinal-type adenocarcinoma and pancreaticobiliary-type adenocarcinoma represent the main histological types of ampullary carcinoma. Furthermore, there exist unusual types and undifferentiated carcinomas. Many carcinomas of intestinal type express the immunohistochemical marker profile of intestinal mucosa (keratin 7?, keratin 20+, MUC2+). Carcinomas of pancreaticobiliary type usually show the immunohistochemical profile of pancreaticobiliary duct mucosa (keratin 7+, keratin 20?, MUC2?). Even poorly differentiated carcinomas, as well as unusual histological types, may conserve the marker profile of the mucosa they developed from. These findings underline the concept of histogenetically different carcinomas of the papilla of Vater which develop either from intestinal- or from pancreaticobiliary-type mucosa of the papilla of Vater. Molecular alterations in ampullary carcinomas are similar to those of colorectal as well as pancreatic carcinomas, although they appear at different frequencies. In future studies, molecular alterations in ampullary carcinomas should be correlated closely with the different histologic tumor types. Consequently, the histologic classification should reflect the histogenesis of ampullary tumors from the two different types of papillary mucosa.     

Demonstration of the mechanism of action of biguanides

Summary Palmitic acid oxidation in rat diaphragm homogenate is depressed by biguanide concentrations that are still incapable of inhibiting oxidative phosphorylation. Glucose oxidation is not directly effected by the same biguanide concentrations: however, the inhibitory effect of palmitic acid on glucose oxidation is partly removed by biguanides. Inhibition of fatty acid oxidation, which accounts for most of the metabolic effects caused by these drugs, can be regarded as the fundamental mechanism of action of biguanides. There is some evidence suggesting that these drugs might interact with carnitine, thus preventing long-chain fatty acids from being transported across the mitochondrial membrane to the site of oxidation. Traduzione a cura degli AA.     

Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease

BACKGROUND AND AIM: Both the clinical presentation and the degree of mucosal damage in coeliac disease vary greatly. In view of conflicting information as to whether the mode of presentation correlates with the degree of villous atrophy, we reviewed a large cohort of patients with coeliac disease. PATIENTS AND METHODS: We correlated mode of presentation (classical, diarrhoea predominant or atypical/silent) with histology of duodenal biopsies and examined their trends over time. RESULTS: The cohort consisted of 499 adults, mean age 44.1 years, 68% females. The majority had silent coeliac disease (56%) and total villous atrophy (65%). There was no correlation of mode of presentation with the degree of villous atrophy (p=0.25). Sixty-eight percent of females and 58% of males had a severe villous atrophy (p=0.052). There was a significant trend over time for a greater proportion of patients presenting as atypical/silent coeliac disease and having partial villous atrophy, though the majority still had total villous atrophy. CONCLUSIONS: Among our patients the degree of villous atrophy in duodenal biopsies did not correlate with the mode of presentation, indicating that factors other than the degree of villous atrophy must account for diarrhoea in coeliac disease.     

血吸虫童虫生长发育及其机制的研究进展

血吸虫童虫是宿主免疫系统攻击的重要靶标,包括皮肤型、肺型和肝门型童虫。宿主分子对童虫生长发育具有重要作用。童虫生长发育机制包括免疫调节、信号转导、性别发育及凋亡等。肌动蛋白、组织蛋白酶、烯醇化酶和葡萄糖基转移酶等分子为血吸虫童虫生长发育的重要分子。本文对血吸虫童虫生长发育及其机制的研究进展做一综述。     

124例耐多药结核分枝杆菌基因突变特征分析

目的对临床分离的耐多药结核分枝杆菌相关基因的突变特征进行分析。方法对124例耐多药结核分枝杆菌以及50株敏感株的耐药相关基因(包括异烟肼inh A、kat G、oxyR-ahp C间隔区以及利福平rpo B)进行序列测定,分析其基因突变情况。结果异烟肼耐药inh A基因突变率为14.5%;kat G基因突变率为70.2%(87/124),主要位于315位;oxyR-ahp C间隔区突变率为15.3%;inh A、kat G两种基因同时突变率75.0%,三种基因同时突变率为89.5%。利福平rpo B基因突变的检出率高达95.2%,突变主要发生在531、526、516位点。结论我省耐多药菌异烟肼耐药相关基因最常见突变为kat G 315、inh A C-T(-15)、axyR-ahp C间隔区(-10)C-T,利福平为rpo B531、526、516。结合MDR-TB耐药相关基因的特征分析,可以建立一种快速、准确、特异的适合于我省的检测结核菌耐多药性的新方法。     

氯硝柳胺悬浮剂的毒性评价

目的评价氯硝柳胺悬浮剂的毒性，为现场大规模应用灭螺提供依据。方法按照中华人民共和国国家标准GB 15670-1995《农药登记毒理学试验方法》和鱼类毒性试验方法进行。结果经口、经皮肤的LDso雌、雄性大鼠均>5 000 mg/kg，经呼吸道的LCso雌、雄性大鼠均>5 000mg/m3，该药经口、经皮肤、经呼吸道毒性均属微毒类药物；兔眼用药后，观察期内无不良反应，对眼无刺激性；皮肤用药后对皮肤无刺激性。与氯硝柳胺原药、氯硝柳胺乙醇胺盐原药和氯硝柳胺乙醇胺盐可湿性粉剂相比，氯硝柳胺悬浮剂对鱼急性毒性最低。结论氯硝柳胺悬浮剂属微毒类药物，对鱼的毒性低于其乙醇胺盐可湿性粉剂，适合于现场应用。     

Assessment of quality of life of parents of children with juvenile chronic arthritis

The aim of the study was to assess the quality of life (QOL) and the psychological status of parents of children with juvenile chronic arthritis (JCA). The QOL, anxiety and depression of the parents of 28 children with JCA were evaluated and compared to those of the parents of 28 healthy children. Mothers of JCA children and mothers of healthy children reported similar QOL. The reported anxiety and depression levels were similar for mothers and fathers in both groups. The parents of children with pauciarticular-type JCA reported lower QOL and higher levels of anxiety and depression than the parents of children with other types, namely polyarticular and systemic JCA. These findings may be explained by the fact that the pauciarticular patients had shorter disease duration and were less frequently seen in the outpatient clinic. The QOL of mothers of children with JCA was found to be slightly impaired in the group of children with pauciarticular JCA. Future larger studies are needed to confirm these results, as the number of subjects in the three groups was rather low. Received: 26 September 2001 / Accepted: 8 February 2002     

Numerical Simulation of the Effect of Rate of Change of Glucose on Measurement Error of Continuous Glucose Monitors

Background

A 5-day in-patient study designed to assess the accuracy of the FreeStyle Navigator® Continuous Glucose Monitoring System revealed that the level of accuracy of the continuous sensor measurements was dependent on the rate of glucose change. When the absolute rate of change was less than 1 mg•dl⁻¹•min⁻¹ (75% of the time), the median absolute relative difference (ARD) was 8.5%, with 85% of all points falling within the A zone of the Clarke error grid. When the absolute rate of change was greater than 2 mg•dl⁻¹•min⁻¹ (8% of the time), the median ARD was 17.5%, with 59% of all points falling within the Clarke A zone.

Method

Numerical simulations were performed to investigate effects of the rate of change of glucose on sensor measurement error. This approach enabled physiologically relevant distributions of glucose values to be reordered to explore the effect of different glucose rate-of-change distributions on apparent sensor accuracy.

Results

The physiological lag between blood and interstitial fluid glucose levels is sufficient to account for the observed difference in sensor accuracy between periods of stable glucose and periods of rapidly changing glucose.

Conclusions

The role of physiological lag on the apparent decrease in sensor accuracy at high glucose rates of change has implications for clinical study design, regulatory review of continuous glucose sensors, and development of performance standards for this new technology. This work demonstrates the difficulty in comparing accuracy measures between different clinical studies and highlights the need for studies to include both relevant glucose distributions and relevant glucose rate-of-change distributions.     

治疗高血压药物的经济学评价

重视高血压治疗中的经济学评价,对利用我国有限的卫生资源来遏制高血压对人民群众的危害有着重要的现实意义。药物经济学对于药物治疗的成本和治疗的结果给予同样的关注。因为治疗高血压的费用,不仅涉及药物价格,还包括患者的危险水平,降压疗效和对临床终点事件的影响,以及治疗的依从性和安全性。因此药物经济学更强调整体成本和价-效比。低危病人,若非药价低廉,治疗的价-效比不够理想。而在高危的患者,价-效比越小越经济而不是药费越便宜越好。